386 related articles for article (PubMed ID: 33097971)
21. Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).
Damato A; Iachetta F; Antonuzzo L; Nasti G; Bergamo F; Bordonaro R; Maiello E; Zaniboni A; Tonini G; Romagnani A; Berselli A; Normanno N; Pinto C
BMC Cancer; 2020 Aug; 20(1):822. PubMed ID: 32867715
[TBL] [Abstract][Full Text] [Related]
22. Comparison of safety and efficacy of fluorouracil + oxaliplatin + irinotecan (FOLFOXIRI) and modified FOLFOXIRI with bevacizumab for metastatic colorectal cancer: data from clinical practice.
Kazama K; Shiozawa M; Numata M; Sugano N; Sato S; Uchiyama M; Sato M; Aoyama T; Tamagawa H; Oshima T; Yukawa N; Rino Y
Int J Colorectal Dis; 2022 Feb; 37(2):337-348. PubMed ID: 34767074
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
[TBL] [Abstract][Full Text] [Related]
24. FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
Pietrantonio F; Fucà G; Rossini D; Schmoll HJ; Bendell JC; Morano F; Antoniotti C; Corallo S; Borelli B; Raimondi A; Marmorino F; Niger M; Boccaccino A; Masi G; Lonardi S; Boni L; de Braud F; Di Bartolomeo M; Falcone A; Cremolini C
Oncologist; 2021 Apr; 26(4):302-309. PubMed ID: 33336844
[TBL] [Abstract][Full Text] [Related]
25. A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial.
Saridaki Z; Androulakis N; Vardakis N; Vamvakas L; Kabouraki E; Kalbakis K; Hatzidaki D; Voutsina A; Mavroudis D; Georgoulias V; Souglakos J
Br J Cancer; 2012 Dec; 107(12):1932-7. PubMed ID: 23169296
[TBL] [Abstract][Full Text] [Related]
26. Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801).
Miwa K; Oki E; Emi Y; Saeki H; Kusumoto T; Akagi Y; Ogata Y; Samura H; Tokunaga S; Ishikawa H; Tanaka T; Sueyoshi S; Higashi H; Matsuda H; Touyama T; Maehara Y;
Int J Clin Oncol; 2016 Feb; 21(1):110-7. PubMed ID: 26037783
[TBL] [Abstract][Full Text] [Related]
27. FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis.
Tomasello G; Petrelli F; Ghidini M; Russo A; Passalacqua R; Barni S
JAMA Oncol; 2017 Jul; 3(7):e170278. PubMed ID: 28542671
[TBL] [Abstract][Full Text] [Related]
28. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES).
Pinter T; Klippel Z; Cesas A; Croitoru A; Decaestecker J; Gibbs P; Hotko Y; Jassem J; Kurteva G; Novotny J; O'Reilly S; Salek T; Reiner M; Morrow PK; Choi MR; Whittaker S; Blanke C
Clin Colorectal Cancer; 2017 Jun; 16(2):103-114.e3. PubMed ID: 28038865
[TBL] [Abstract][Full Text] [Related]
29. Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT).
Bennouna J; Phelip JM; André T; Asselain B; Sébastien Koné ; Ducreux M
Clin Colorectal Cancer; 2017 Jun; 16(2):129-140.e4. PubMed ID: 28277294
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and Safety of Modified FOLFOXIRI+α in the Treatment of Advanced and Recurrent Colorectal Cancer: A Single-center Experience.
Kobayashi K; Yamaguchi S; Ito S; Torashima Y; Inoue Y; Okada S; Enjoji T; Tetsuo H; Kuba S; Kosaka T; Adachi T; Hidaka M; Yamanouchi K; Kanetaka K; Takatsuki M; Eguchi S
Intern Med; 2020 May; 59(10):1239-1245. PubMed ID: 32074573
[TBL] [Abstract][Full Text] [Related]
31. Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study.
Kitagawa Y; Osumi H; Shinozaki E; Ota Y; Nakayama I; Suzuki T; Wakatsuki T; Ogura M; Ooki A; Takahari D; Suenaga M; Chin K; Yamaguchi K
BMC Cancer; 2020 Apr; 20(1):358. PubMed ID: 32345249
[TBL] [Abstract][Full Text] [Related]
32. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.
Falcone A; Ricci S; Brunetti I; Pfanner E; Allegrini G; Barbara C; Crinò L; Benedetti G; Evangelista W; Fanchini L; Cortesi E; Picone V; Vitello S; Chiara S; Granetto C; Porcile G; Fioretto L; Orlandini C; Andreuccetti M; Masi G;
J Clin Oncol; 2007 May; 25(13):1670-6. PubMed ID: 17470860
[TBL] [Abstract][Full Text] [Related]
33. Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer.
Bazarbashi S; Aljubran A; Alzahrani A; Mohieldin A; Soudy H; Shoukri M
Cancer Med; 2015 Oct; 4(10):1505-13. PubMed ID: 26207614
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Cremolini C; Casagrande M; Loupakis F; Aprile G; Bergamo F; Masi G; Moretto R R; Pietrantonio F; Marmorino F; Zucchelli G; Tomasello G; Tonini G; Allegrini G; Granetto C; Ferrari L; Urbani L; Cillo U; Pilati P; Sensi E; Pellegrinelli A; Milione M; Fontanini G; Falcone A
Eur J Cancer; 2017 Mar; 73():74-84. PubMed ID: 27986363
[TBL] [Abstract][Full Text] [Related]
35. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
[TBL] [Abstract][Full Text] [Related]
36. FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies.
Antoniotti C; Germani MM; Rossini D; Lonardi S; Pietrantonio F; Santini D; Marmorino F; Allegrini G; Daniel F; Raimondi A; Borelli B; Zaniboni A; Conca V; Abraham J; Spetzler D; Maiello E; Boccaccino A; Passardi A; Giordano M; Tamburini E; Korn MW; Masi G; Cremolini C
Eur J Cancer; 2022 May; 167():23-31. PubMed ID: 35366570
[TBL] [Abstract][Full Text] [Related]
37. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.
Martin RC; Scoggins CR; Schreeder M; Rilling WS; Laing CJ; Tatum CM; Kelly LR; Garcia-Monaco RD; Sharma VR; Crocenzi TS; Strasberg SM
Cancer; 2015 Oct; 121(20):3649-58. PubMed ID: 26149602
[TBL] [Abstract][Full Text] [Related]
38. Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST).
Tsai HL; Huang CW; Lin YW; Wang JH; Wu CC; Sung YC; Chen TL; Wang HM; Tang HC; Chen JB; Ke TW; Tsai CS; Huang HY; Wang JY
Eur J Cancer; 2020 Oct; 138():19-29. PubMed ID: 32829105
[TBL] [Abstract][Full Text] [Related]
39. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial.
Antoniotti C; Rossini D; Pietrantonio F; Catteau A; Salvatore L; Lonardi S; Boquet I; Tamberi S; Marmorino F; Moretto R; Ambrosini M; Tamburini E; Tortora G; Passardi A; Bergamo F; Kassambara A; Sbarrato T; Morano F; Ritorto G; Borelli B; Boccaccino A; Conca V; Giordano M; Ugolini C; Fieschi J; Papadopulos A; Massoué C; Aprile G; Antonuzzo L; Gelsomino F; Martinelli E; Pella N; Masi G; Fontanini G; Boni L; Galon J; Cremolini C;
Lancet Oncol; 2022 Jul; 23(7):876-887. PubMed ID: 35636444
[TBL] [Abstract][Full Text] [Related]
40. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule.
Masi G; Allegrini G; Cupini S; Marcucci L; Cerri E; Brunetti I; Fontana E; Ricci S; Andreuccetti M; Falcone A
Ann Oncol; 2004 Dec; 15(12):1766-72. PubMed ID: 15550581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]